Efavirenz

Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[1].

Product Specifications

CAS Number

[154598-52-4]

Product Name Alternative

DMP 266; EFV; L-743726

UNSPSC

12352005

Hazard Statement

H242, H302, H360, H410

Target

Autophagy; Endogenous Metabolite; HIV; Parasite; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Efavirenz.html

Purity

99.93

Solubility

DMSO : ≥ 38 mg/mL

Smiles

ClC1=CC=C(NC(O[C@]2(C#CC3CC3)C(F)(F)F)=O)C2=C1

Molecular Formula

C14H9ClF3NO2

Molecular Weight

315.68

Precautions

H242, H302, H360, H410

References & Citations

[1]Young SD, et al. L-743, 726 (DMP-266) : a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39 (12) :2602-5.|[2]Held DM, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281 (35) :25712-22.|[3]Grobler JA, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282 (11) :8005-10.